Spirulina.Guru

Science

Spirulina and mast cell activation syndrome.

Mast cell activation syndrome (MCAS) involves clonal or reactive mast cell populations that degranulate inappropriately, releasing histamine, prostaglandin D<sub>2</sub>, leukotrienes C4/D4, and tryptase. Spirulina’s GLA/DGLA pathway reduces leukotriene production by competing at 5-lipoxygenase — a mechanistically relevant anti-mast cell action. However, spirulina as a biological product may also trigger reactions in hypersensitive patients. The start-low protocol is essential.

MCAS pathophysiology

  • Mast cell mediators:Mast cells release preformed mediators from granules (histamine, tryptase, heparin — within seconds of degranulation) and synthesise new mediators (prostaglandin D2via COX-2, leukotrienes LTC4/LTD4 via 5-LOX, PAF, cytokines — within minutes to hours). The combined release causes multi-system symptoms: flushing, urticaria, anaphylaxis, GI cramping and diarrhoea, brain fog, fatigue, tachycardia, and orthostatic intolerance.
  • Classification:MCAS is classified as primary (clonal: systemic mastocytosis, monoclonal MCAS), secondary (reactive: IgE-mediated, complement-triggered), or idiopathic. The majority of MCAS diagnoses in current practice are idiopathic or secondary — patients with dysautonomia (POTS), hEDS, and Long COVID have disproportionately high MCAS rates.
  • Triggers:MCAS triggers are highly individual and idiosyncratic. Common triggers include: temperature change, exercise, certain foods, fragrances, medications, and biological supplements. Any new substance can be a trigger in sensitised patients.

GLA/DGLA and the 5-LOX pathway

  • Spirulina contains approximately 500–1,000 mg gamma-linolenic acid (GLA) per 10 g serving. GLA is elongated to DGLA (dihomo-gamma-linolenic acid) in cells. DGLA competes with arachidonic acid at 5-lipoxygenase (5-LOX), producing anti-inflammatory 15-HETrE rather than the pro-inflammatory LTC4/LTD4 that drives mast cell-mediated bronchoconstriction and vascular permeability.
  • This is the same pathway addressed by leukotriene receptor antagonists (montelukast) — montelukast blocks LTD4 at the CysLT1 receptor; spirulina’s GLA/DGLA reduces LTC4/LTD4 production upstream. Mechanistically complementary to montelukast in MCAS where leukotriene-driven symptoms predominate.
  • The COX-2 prostaglandin pathway (PGD2in mast cells) is less directly addressed by spirulina; NSAIDs reduce PGD2 but are often poorly tolerated in MCAS.

Phycocyanobilin relevance

  • NOX2 inhibition reduces superoxide-mediated mast cell priming. Oxidative stress lowers the degranulation threshold in mast cells — reducing the oxidative microenvironment may raise the activation threshold.
  • NF-κB inhibition reduces the transcription of mast cell-promoting cytokines (SCF/c-Kit ligand, IL-33, IL-4) that amplify mast cell proliferation and sensitivity.

CRITICAL: spirulina as a potential MCAS trigger

  • Spirulina is a biological product containing multiple proteins, polysaccharides, and pigments, any of which may be MCAS triggers in individual patients. IgE sensitisation to spirulina proteins is documented (as in all food allergies). Mast cell degranulation triggered by spirulina-specific IgE would produce histamine, tryptase, and leukotriene release — exactly the mediators spirulina is intended to reduce.
  • The start-low imperative:Begin at 0.1 g (approximately one-twentieth of a standard dose). This is achieved by dissolving 1 g spirulina in 100 ml water and consuming 10 ml (one-tenth). Stay at 0.1 g for one week, monitoring for any MCAS symptom worsening in the 24–48 hours after each dose. If tolerated: increase by 0.1 g per week. Target dose 1–3 g/day; many MCAS patients do not tolerate full standard doses.
  • If any MCAS symptom worsening occurs after a dose increase — flushing, urticaria, GI cramping, tachycardia, brain fog worsening — return to the previous dose for 2 weeks before attempting to increase again.
  • Some MCAS patients cannot tolerate spirulina at any dose. This is individual; the GLA/DGLA mechanism does not guarantee tolerability in mast-cell-hypersensitive patients.

Histamine content of spirulina

  • Spirulina itself has low histamine content (<10 mg/kg in fresh product, well below the 50 mg/kg threshold in aged/fermented foods). Fresh, high-quality spirulina is not a histamine-rich food. However, degraded or old spirulina may have elevated biogenic amines. Quality CoA for biogenic amines from the manufacturer is relevant for MCAS patients.

Drug interactions in MCAS

  • Montelukast (CysLT1 antagonist):No pharmacokinetic interaction; complementary mechanisms (upstream leukotriene reduction vs receptor blockade).
  • Antihistamines (cetirizine, loratadine, fexofenadine — H1; famotidine — H2):No pharmacokinetic interaction with spirulina. H1 and H2 blocker combinations are standard MCAS management; spirulina’s leukotriene pathway addresses a different mediator class.
  • Cromolyn sodium (mast cell stabiliser):No interaction. Cromolyn prevents degranulation directly; spirulina reduces the pro-inflammatory output of degranulation. Complementary approaches.

Practical guidance

  • Start at 0.1 g/day; increase by 0.1 g per week; monitor 24–48 hours post-dose for any MCAS symptom worsening
  • Use high-quality spirulina with CoA for heavy metals and biogenic amines; avoid old or degraded product
  • If any reaction: pause and consult with immunologist or MCAS-experienced practitioner before restarting
  • The GLA/5-LOX leukotriene reduction mechanism is the primary MCAS-relevant action of spirulina; phycocyanobilin NOX2 inhibition is secondary
  • Inform prescribing doctor of all supplements — particularly relevant in MCAS where polypharmacy is common

Related reading

Get the weekly digest

Curated science, recipes, and brand intel — once a week, no spam, unsubscribe in one click.